Monitoring Prostate Cancer with Tissue Polypeptide-Specific Antigen
Author Information
Author(s): G Theyer, S Holub, A Durer, S Andert, I Haberl, U Theyer, G Hamilton
Primary Institution: Wilhelminenspital der Stadt Wien
Hypothesis
Can tissue polypeptide-specific antigen (TPS) effectively monitor tumor progression in prostate cancer patients undergoing intermittent androgen suppression therapy?
Conclusion
TPS is a highly sensitive but not tumor-specific marker for monitoring disease progression in prostate cancer patients.
Supporting Evidence
- TPS levels fell during periods of tumor regression and increased before PSA levels during treatment cessation.
- Non-specific elevations of TPS were found in 8 out of 23 patients, indicating limitations in its specificity.
- All patients showed a decrease in tumor volume during androgen suppression therapy.
Takeaway
Doctors are trying to see if a new test called TPS can help track how prostate cancer is doing when patients take breaks from their hormone treatments.
Methodology
The study involved measuring serum levels of TPS and PSA in 23 prostate cancer patients undergoing intermittent androgen suppression therapy.
Potential Biases
Potential for non-malignant causes of TPS elevation complicating interpretation.
Limitations
TPS may show non-specific elevations due to factors unrelated to tumor growth, limiting its specificity.
Participant Demographics
All participants were men with advanced prostate cancer, specifically those with disseminated adenocarcinoma.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website